KOPRAN Kopran Q3 FY25 results (Oct–Dec 2024) and concall
Kopran Limited announced the Board approval for the merger of Kopran Laboratories Limited on March 20, 2025. This strategic move aims to integrate Kopran Limited into the rapidly growing Indian diagnostic market, leveraging synergies to become a comprehensive healthcare company. Kopran Laboratories, valued at INR 256 crores, operates on a robust annuity-based model, targeting 28-30% EBITDA margins, and has demonstrated significant growth, with its FY24 top line increasing by 45% to INR 103 crores. The merger is anticipated to be EPS accretive and enhance shareholder value.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 152 | 166 |
| EBITDA | 15 | 20 |
| Net profit | 7 | 10 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
